Current Report Filing (8-k)
February 12 2016 - 7:04AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event
reported): February 8, 2016
IDEXX LABORATORIES, INC.
(Exact name of registrant as specified
in its charter)
Delaware |
000-19271 |
01-0393723 |
(State or other jurisdiction |
(Commission File Number) |
(IRS Employer Identification No.) |
of incorporation) |
|
|
One IDEXX Drive, Westbrook, Maine |
04092 |
(Address of principal executive offices) |
(ZIP Code) |
207.556.0300
(Registrant's telephone number, including
area code)
Not Applicable
(Former name or former address, if changed
since last report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. to Form 8-K):
o |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
o |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
o |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
o |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 5.02 |
Departure of Directors or Certain Officers; Election of Directors; Appointment of |
|
Certain Officers; Compensatory Arrangements of Certain Officers. |
On February 8, 2016, Johnny D. Powers, Ph.D.,
Executive Vice President, announced that he will be retiring from the Company in May 2016 and is stepping down from his current
position effective February 8, 2016. Dr. Powers will remain employed at the Company until May 6, 2016 in order to assist in the
transition of his responsibilities. In connection with Dr. Powers’s retirement, the Company agreed to pay Dr. Powers a lump
sum of $305,760, the amount of $436,800 in 26 bi-weekly installments, and certain other benefits, all in consideration of Dr. Powers’s
agreement to certain non-competition and non-solicitation obligations and a standard release of claims.
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
IDEXX LABORATORIES, INC. |
|
|
Date: February 12, 2016 |
By: |
/s/ Jacqueline L. Studer |
|
|
Jacqueline L. Studer |
|
|
Corporate Vice President, General Counsel |
|
|
and Secretary |
IDEXX Laboratories (NASDAQ:IDXX)
Historical Stock Chart
From Aug 2024 to Sep 2024
IDEXX Laboratories (NASDAQ:IDXX)
Historical Stock Chart
From Sep 2023 to Sep 2024